CG Oncology, Inc. (CGON) Institutional Ownership

Ownership Summary

CG Oncology, Inc. (NASDAQ:CGON) has 190 institutional investors that have filed 13F reports for the period ending December 2025.

• These investors collectively held 102.9% of CG Oncology's outstanding shares in December 2025, up from 102.5% in September 2025.
• Their total shares held in CGON increased 6.34% from the prior quarter, while the number of investors in CG Oncology increased 36.69% year over year.
• Activity in CGON broke down as 110 buyers, 53 sellers, and 27 unchanged among 190 total holders.
• Combined, these investors held 78.95Mn shares in CGON for December 2025, up by 4.71Mn shares quarter on quarter, and up 9.66Mn shares year over year.
• RTW INVESTMENTS, LP leads ownership in CGON with 6.98Mn shares as of December 31, 2025, equal to 9.1% of outstanding shares.
• Leading buyers of CG Oncology shares for the quarter ending December 2025 were T. Rowe Price Investment Management, Inc. (6.26Mn), RTW INVESTMENTS, LP (4.97Mn), PRICE T ROWE ASSOCIATES INC /MD/ (3.65Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (3.1Mn), VANGUARD CAPITAL MANAGEMENT LLC (3.03Mn).
• The biggest sellers of CG Oncology for the quarter ending December 2025 included Seven Fleet Capital Management LP (2.95Mn), Goldman Sachs Group Inc (1.49Mn), Pictet Asset Management Holding SA (951.52K), BRAIDWELL LP (885.79K), Opaleye Management Inc. (725.2K).
• Business Quant data shows the 10 biggest positions in CG Oncology as of December 2025 are held by RTW INVESTMENTS, LP (6.98Mn), T. Rowe Price Investment Management, Inc. (6.72Mn), Decheng Capital LLC (6.37Mn), WELLINGTON MANAGEMENT GROUP LLP (5.37Mn), BlackRock, Inc. (5.06Mn), FMR LLC (3.76Mn), TCG Crossover Management, LLC (3.67Mn), PRICE T ROWE ASSOCIATES INC /MD/ (3.65Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (3.1Mn), VANGUARD CAPITAL MANAGEMENT LLC (3.03Mn).